James M. Prosser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
James M. Prosser has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Lisa Janet Cohen
Beth Israel Medical Center/Albert Einstein College of Medicine, New York, NY 10003, USA
3 shared publications Igor I. Galynker
2 shared publicationsMatthew Steinfeld
From the Department of Psychiatry and Behavioral Sciences, Beth Israel Medical Center, Albert Einstein College of Medicine, New York, NY
2 shared publications- Annie Steele
The Department of Psychiatry and Behavioral Sciences, Beth Israel Medical Center, Albert Einstein College of Medicine, First Ave at 16th St, New York, NY 10003, USA
1 shared publication D Eisenberg
Department of Psychiatry and Behavioral Sciences, Beth Israel Medical Center, Albert Einstein College of Medicine, New York, NY 10003, USA
1 shared publication- Daniel Eisenberg
National Institute of Mental Health, Division of Clinical Research. Bldg. 10, Magnusen CC, 10 Center Dr. Bethesda, MD, USA
1 shared publication
Latest Publications
- 1 March 2011
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 5 (1) , 50-56
The Effect of Pain on Stroop Performance in Patients With Opiate Dependence in Sustained Remission
Objectives: We have demonstrated previously that former opiate-dependent subjects treated and detoxified from methadone maintenance therapy suffer deficits in neuropsychological performance and have abnormal pain thresholds. This study examined the impact of pain on the performance of the Stroop test, a well-known test of neuropsychological performance. Methods: Twenty-three former opiate-dependent subjects treated and detoxified from methadone maintenance therapy and 24 comparison (COM) subjects without a history of opiate dependence were tested using the Stroop test under 2 conditions: Stroop under usual conditions and Stroop under painful conditions. The painful condition was induced using a Medoc Thermal Sensory Analyzer to deliver a heat stimulus at and below the subjects' pain threshold. Results: COM subjects performed better than former opiate-dependent subjects, and females performed better than males on the Stroop under usual conditions. These differences were missing when the Stroop under painful conditions was performed. Analysis of these differences revealed that male former opiate-dependent subjects had a larger improvement in Stroop scores under the painful condition than male COM subjects or females of either group. Conclusions: Performance on a neuropsychological test was adversely impacted by previous opiate addiction, and these effects seemed to be greater in males compared with females. Treated patients with opiate dependence showed improvement in Stroop test performance under painful conditions, and this improvement was greater in males than females.
- 1 March 2011
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 5 (1) , 50-56
The Effect of Pain on Stroop Performance in Patients With Opiate Dependence in Sustained Remission
Objectives: We have demonstrated previously that former opiate-dependent subjects treated and detoxified from methadone maintenance therapy suffer deficits in neuropsychological performance and have abnormal pain thresholds. This study examined the impact of pain on the performance of the Stroop test, a well-known test of neuropsychological performance. Methods: Twenty-three former opiate-dependent subjects treated and detoxified from methadone maintenance therapy and 24 comparison (COM) subjects without a history of opiate dependence were tested using the Stroop test under 2 conditions: Stroop under usual conditions and Stroop under painful conditions. The painful condition was induced using a Medoc Thermal Sensory Analyzer to deliver a heat stimulus at and below the subjects' pain threshold. Results: COM subjects performed better than former opiate-dependent subjects, and females performed better than males on the Stroop under usual conditions. These differences were missing when the Stroop under painful conditions was performed. Analysis of these differences revealed that male former opiate-dependent subjects had a larger improvement in Stroop scores under the painful condition than male COM subjects or females of either group. Conclusions: Performance on a neuropsychological test was adversely impacted by previous opiate addiction, and these effects seemed to be greater in males compared with females. Treated patients with opiate dependence showed improvement in Stroop test performance under painful conditions, and this improvement was greater in males than females.
- 1 October 2009
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 104 (3) , 228-240
Sustained attention in patients receiving and abstinent following methadone maintenance treatment for opiate dependence: Performance and neuroimaging results
- 1 October 2009
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 104 (3) , 228-240
Sustained attention in patients receiving and abstinent following methadone maintenance treatment for opiate dependence: Performance and neuroimaging results
- Open Access
- 26 May 2009
- Published by Springer Nature in BMC Psychiatry
- Vol. 9 (1) , 25
A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study
Because a large proportion of patients with panic attacks receiving approved pharmacotherapy do not respond or respond poorly to medication, it is important to identify additional therapeutic strategies for the management of panic symptoms. This article describes a randomized, rater-blind study comparing low-dose risperidone to standard-of-care paroxetine for the treatment of panic attacks. Fifty six subjects with a history of panic attacks were randomized to receive either risperidone or paroxetine. The subjects were then followed for eight weeks. Outcome measures included the Panic Disorder Severity Scale (PDSS), the Hamilton Anxiety Scale (Ham-A), the Hamilton Depression Rating Scale (Ham-D), the Sheehan Panic Anxiety Scale-Patient (SPAS-P), and the Clinical Global Impression scale (CGI). All subjects demonstrated a reduction in both the frequency and severity of panic attacks regardless of treatment received. Statistically significant improvements in rating scale scores for both groups were identified for the PDSS, the Ham-A, the Ham-D, and the CGI. There was no difference between treatment groups in the improvement in scores on the measures PDSS, Ham-A, Ham-D, and CGI. Post hoc tests suggest that subjects receiving risperidone may have a quicker clinical response than subjects receiving paroxetine. We can identify no difference in the efficacy of paroxetine and low-dose risperidone in the treatment of panic attacks. Low-dose risperidone appears to be tolerated equally well as paroxetine. Low-dose risperidone may be an effective treatment for anxiety disorders in which panic attacks are a significant component. ClinicalTrials.gov Identifier: NCT100457106
- 26 May 2009
- Published by Springer Nature in BMC Psychiatry
- Vol. 9 (1) , 25
Open AccessA comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study
Because a large proportion of patients with panic attacks receiving approved pharmacotherapy do not respond or respond poorly to medication, it is important to identify additional therapeutic strategies for the management of panic symptoms. This article describes a randomized, rater-blind study comparing low-dose risperidone to standard-of-care paroxetine for the treatment of panic attacks. Fifty six subjects with a history of panic attacks were randomized to receive either risperidone or paroxetine. The subjects were then followed for eight weeks. Outcome measures included the Panic Disorder Severity Scale (PDSS), the Hamilton Anxiety Scale (Ham-A), the Hamilton Depression Rating Scale (Ham-D), the Sheehan Panic Anxiety Scale-Patient (SPAS-P), and the Clinical Global Impression scale (CGI). All subjects demonstrated a reduction in both the frequency and severity of panic attacks regardless of treatment received. Statistically significant improvements in rating scale scores for both groups were identified for the PDSS, the Ham-A, the Ham-D, and the CGI. There was no difference between treatment groups in the improvement in scores on the measures PDSS, Ham-A, Ham-D, and CGI. Post hoc tests suggest that subjects receiving risperidone may have a quicker clinical response than subjects receiving paroxetine. We can identify no difference in the efficacy of paroxetine and low-dose risperidone in the treatment of panic attacks. Low-dose risperidone appears to be tolerated equally well as paroxetine. Low-dose risperidone may be an effective treatment for anxiety disorders in which panic attacks are a significant component. ClinicalTrials.gov Identifier: NCT100457106
- Open Access
- 19 November 2008
- Published by Springer Nature in Substance Abuse Treatment, Prevention, and Policy
- Vol. 3 (1) , 23
Character pathology and neuropsychological test performance in remitted opiate dependence
Cognitive deficits and personality pathology are prevalent in opiate dependence, even during periods of remission, and likely contribute to relapse. Understanding the relationship between the two in vulnerable, opiate-addicted patients may contribute to the design of better treatment and relapse prevention strategies.
- 19 November 2008
- Published by Springer Nature in Substance Abuse Treatment, Prevention, and Policy
- Vol. 3 (1) , 23
Open AccessCharacter pathology and neuropsychological test performance in remitted opiate dependence
Cognitive deficits and personality pathology are prevalent in opiate dependence, even during periods of remission, and likely contribute to relapse. Understanding the relationship between the two in vulnerable, opiate-addicted patients may contribute to the design of better treatment and relapse prevention strategies.
- 1 June 2008
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 95 (3) , 237-244
Abnormal heat and pain perception in remitted heroin dependence months after detoxification from methadone-maintenance
- 1 June 2008
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 95 (3) , 237-244
Abnormal heat and pain perception in remitted heroin dependence months after detoxification from methadone-maintenance
- 1 October 2006
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 84 (3) , 240-247
Neuropsychological functioning in opiate-dependent subjects receiving and following methadone maintenance treatment
- 1 October 2006
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 84 (3) , 240-247
Neuropsychological functioning in opiate-dependent subjects receiving and following methadone maintenance treatment